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Allergic rhinitis (AR) is a major health concern and numerous guidelines have been
developed to standardize and to improve the management of this disease. As in many other
areas of medicine, the methodology of the AR guidelines has evolved from opinion-based
to evidence-based medicine. Although evidence-based medicine has many benefits, it also
has limitations and cannot cancel the value of the individual clinical expertize.
More important than the methodology of guideline development is the efficacy of
guidelines to change patient and physician behaviour and to improve clinical outcomes. At
present, however, studies on the effectiveness of guidelines are few. The International
Consensus on Rhinitis from 1994 is the only guideline for AR that has been assessed for its
effects on health outcomes. Furthermore, there is a lack of valid and reliable instruments
to assess physician’s and patient’s attitude towards and compliance with guideline
recommendations.
There is no single effective way to ensure the use of guidelines into practice, but a
carefully developed and multifaceted dissemination and implementation strategy and
targeting and adapting guideline recommendations to the local and individual level are key
elements. The final and most important step of putting guidelines into practice occurs at
the level of the patient. Patients should be considered as effective partners in health care.
Education of the patient and efforts to change patient’s behaviour can maximize
compliance, increase satisfaction and optimize health outcomes.
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Clinical guidelines are systematically developed statements
to assist practitioners and patients in making decisions about
appropriate and effective health care in specific circum-
stances.1 Over the last 2 decades, clinical practice guide-
lines have gained much interest, both in medical education
and in clinical practice, as a tool to synthesize clinical
information and to improve the quality of health care. A
large amount of national and international guidelines,
covering diverse areas of medicine—including allergic
rhinitis (AR)—have been published, and guideline users
may even get overwhelmed and confused by this extensive
offer.
To ensure the quality of clinical guidelines, increasing
attention is paid to the methodology of guideline develop-
ment and to the accuracy and validity of the recommenda-
tions.2 Key issues in the highly complex stepwise process of
guideline development are listed in Table 1.
In this review we discuss the current international
guidelines for AR, with a special focus on the most
recent AR guidelines: the ARIA guidelines. We critically
appraise the methodology of guideline development, the
composition of the expert panel, the validity and global
applicability of guidelines for AR. Furthermore, we address
the barriers that may rise when translating scientific
knowledge into relevant and accessible information for the
practitioner and we discuss the importance of a carefully
planned and multifaceted dissemination and implementa-
tion strategy.Table 1 Key issues of guideline development.
– Composition of a multidisciplinary panel, including
representatives of the target group(s)
– Systematic review of the available scientific
knowledge
– Formulation of high-quality information and
recommendations, based on the best available
evidence from research
– Targeting and adaptation of the guidelines to the end-
users
– Wide dissemination and implementation of guidelines
into clinical practice
– Monitoring of compliance with the guideline
recommendations among users
– Regularly updatingClinical guidelines for AR: the current situationBefore 2001, European and American guidelines for the
management of allergic and non-allergic rhinitis were
developed, based on expert opinion.3–6 The American
guidelines for rhinitis5 were published in 1996 and were
updated 2 years later.6 They represent a state-of-the-art
revision of the clinical characteristics, the (differential)
diagnosis and treatment of rhinitis. But, as they do not
provide practical recommendations, guiding practitioners in
the management of their rhinitis patients, strictly, they do
not fit into the concept of ‘clinical practice guidelines’ and
will not be further discussed. The European guidelines3,4
contain very similar information to the American ‘guide-
lines’, but a prominent feature of the European guidelines is
that they include stepwise treatment algorithms for rhinitis,
similar to the Global Initiative for Asthma (GINA) guidelines
for asthma.8 The guidelines from the European Academy of
Allergology and Clinical Immunology (EAACI)4 were aimed as
an update of the previous International Consensus State-
ment on Rhinitis3 in response to the increasing insights in the
pathophysiology underlying allergic inflammation and the
continuous modifications and improvements in allergic
disease management during the 1990s. Furthermore,
whereas the International Consensus Statement on Rhinitis
was especially developed for general practitioners (GPs),
and only accounted for patients with mild or moderate
disease, the newer EAACI guidelines were also aimed for
specialists and also consider patients with severe disease.
In 1999, the Allergic Rhinitis and its Impact on Asthma
(ARIA) Working Group was founded under the initiative of
the World Health Organization (WHO). The ARIA guidelines,
resulting from this collaboration, are directed towards
managing rhinitis and asthma as different manifestations
of one ‘united airway disease’.7 They also recommend a
stepwise treatment strategy for AR, but unlike the European
guidelines, which are based on the opinion of a panel of
experts, and, of course, on the available literature, the ARIA
guidelines are evidence-based.
In order to provide a more appropriate management, the
ARIA group reviewed and changed the classification of AR. It
became obvious that classifying rhinitis, based on the type
of allergen exposure (into seasonal, perennial and by
extension occupational), is not applicable in all patients
and all regions. Therefore, ARIA re-classified AR as ‘inter-
mittent’ or ‘persistent’, on the basis of the duration, rather
than on the time-of-year of symptom manifestation.7 In
addition, the terms ‘intermittent’ and ‘persistent’ are
adapted from the (GINA) classification for asthma,8 which
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Table 2 Classification schemes of statements of evi-
dence, adapted from Shekelle et al. 17
Category of evidence
Ia: Evidence from meta-analysis or randomized controlled
trials
Ib: Evidence from at least one randomized controlled
trial
IIa: Evidence from at least one controlled study without
randomization
IIb: Evidence from at least one type other type of quasi-
experimental study
III: Evidence from non-experimental descriptive studies,
such as comparative studies, correlation studies and
case-control studies
IV: Evidence from expert committee reports or opinions
or clinical experience of respected authorities or both
Strength of evidence of recommendations
A: Directly based on category I evidence
B: Directly based on category II evidence or extrapolated
recommendation from category I evidence
C: Directly based on category III evidence or extrapolated
recommendation from category I or II evidence
D: Directly based on category IV evidence or extrapolated
recommendation from category I, II or III evidence
H.V. Hoecke, P.V. Cauwenberge708facilitates understanding between otorhinolaryngologist and
pulmonologist. Recently, this modification in classification of
AR has been validated in large epidemiological trials in the
general population,9,10 in primary care practice11 and in
specialty practice.12 Furthermore, ARIA grades the severity
of AR as mild or moderate-severe, based on the impact of AR
on Quality of Life issues, rather than on rating (nasal)
symptom scores. According to the duration and severity of
disease, a treatment algorithm with step-up and step-down
options is recommended.
Evidence-based medicine and evidence-based
guidelines
The methodology of guideline development has evolved
from basing recommendations on expert opinion (opinion-
based medicine) to relying on a systematic review of
evidence regarding the efficacy of various procedures and
interventions (evidence-based medicine).13 For health care
practitioners it is almost impossible to keep up-to-date with
the medical literature. It is even more difficult to critically
appraise the value of research findings and to apply
evidence from research in medical practice. To allow
clinicians to efficiently use the information from systematic
research in making decisions about the care of the individual
patient, the process of preparing and providing clinical
practice guidelines, based on the best-available evidence
from research, has become essential. The recommendations
of these ‘evidence-based guidelines’ are linked to a specific
evidence background, which is identified through an
extensive literature search, critically evaluated and rated
by a specific grading system.14
Identification and assessment of evidence
Critical examination of evidence from clinical research is
best done by performing a systematic review. Of course, the
quality of the collected evidence must be evaluated
following pre-established criteria. The consolidated stan-
dards of reporting trials (CONSORT) and the quality of
reporting of meta-analyses (QUORUM) statements in parti-
cular, are intended to improve the reporting of randomized
controlled trials and meta-analyses. In addition, they enable
readers, reviewers, researchers and editors to understand a
trial’s conduct and to assess the validity of its results in a
stepwise manner.15
The Cochrane Library is a key source for evidence on
health care interventions. The Cochrane Collaboration is
organized in about 50 study groups, covering different areas
of interest in medical research. In general, the comprehen-
sive systematic reviews of the Cochrane Collaboration are
more systematic and demonstrate less publication and
reference bias than systematic reviews published in paper
journals. A rigorous methodology is applied, characterized
by an extensive review of published and pre-published data,
obtained through database- and hand-searching, and the
process of post-publication review is promoted.16,17 But
still, even systematic Cochrane reviews are not free of
errors and bias and must be interpreted with caution.2,18
Systematic reviews are sometimes criticized for their
failure to offer specific guidance, which is often due to fewassessments of outcome measures in the primary studies
that they analyse.2,19 Furthermore, not for every subject
area systematic reviews are available and, despite a
thorough and hand-based search, it is not possible to have
access to and to review all relevant study results. For some
major issues, such as the role of allergen avoidance in the
treatment of AR and asthma, there still is a lack of evidence,
and more results of large-scale trials are needed.
Grading evidence
For guideline users, it is important to know how much
confidence they can place in guideline recommendations
and their underlying evidence. The quality of clinical
guidelines indeed depends on the evidence and the
judgments they are based on.18 Several grading systems
are currently available to evaluate the level of evidence and
the strength of the recommendations and, therefore, to
help people making well-informed decisions. The ARIA
guidelines followed the grading system of the Agency for
Health Care Policy and Research (AHCPR), which has been a
reference for many years17 (Table 2).
Other, more recent grading systems include the Scottish
Intercollegiate Guidelines Network (SIGN)20 and Oxford
Centre for Evidence-Based Medicine (OCEBM) systems.21
Although these different classification systems all share the
same basic structure, they demonstrate differences in
terminology and in gradation of evidence from specific
publication types, which is of course confusing and limits
easy communication.14,18 In addition, a critical assessment
by the Grades of Recommendation Assessment, Develop-
ment and Evaluation (GRADE) Working Group for the
sensibility of six prominent approaches for grading levels
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that all these classification systems have important short-
comings.22
For the ARIA guidelines, the evidence for the recom-
mended pharmacotherapy and immunotherapy for AR
treatments was examined by the report panel and was
graded according to the AHCPR system. The evidence for
pharmacotherapy and immunotherapy in AR treatment has
shown to be particularly strong (category A strength of
evidence); evidence for allergen avoidance on the other
hand, is limited (categorie D strength of evidence).7 An
important limitation of this classification method, however,
is that there is no grading for ‘negative’ results. Recently,
the efficacy of sublingual immunotherapy (SLIT) in AR was
evaluated by the Cochrane Collaboration in a meta-analysis
of 22 double-blind placebo-controlled trials. Four studies
enroled exclusively children, and these could not establish a
significant reduction in the children’s symptoms and
medication scores when they were treated with SLIT.23 The
classification scheme of Shekelle, however, does not provide
a category that allows us to grade the recommendation
strength of SLIT administration in children with AR.
Another consideration is the sometimes questionable
clinical relevance of the strength of evidence supporting a
specific recommendation. For chromones for instance,
placebo-controlled trials have demonstrated that these
agents are safe and effective in the treatment or prophy-
laxis of AR symptoms, which corresponds with a category A
strength of evidence. In clinical practice, however, the use
of chromones is limited, as they have demonstrated to be
clearly less effective than other common anti-allergy
medications, such as H1-antihistamines and intranasal
glucocorticosteroids.Table 3 Composition of the expert panel at the basis of
the development of guidelines for allergic rhinitis.
European
guidelines
1994
European
guidelines
2000
ARIA
guidelines
2001
Nr of group
members
18 14 37
Panel composition
Specialists Yes Yes Yes
GPs No No Yes
Countries
represented
11 7 17
Continents
represented
3 2 4
Gender (M/F) 16/2 12/2 30/7
University/ 16/2 14/0 34/3
non-university
affiliated
Conflict of interest Not
disclosed
Not
disclosed
Reported to
WHO(pharmaceutical
industry)Drawbacks on evidence-based medicine
Evidence-based medicine has become an increasingly
important concept in medicine. The benefits of the
methodology to provide a convenient logical framework
from which the quality and relevance of clinical studies may
be assessed in an unbiased manner24 are growing in many
contexts and are well described. Less acknowledged,
however, is that evidence-based medicine also has limita-
tions. For many clinical questions and management deci-
sions, there remains a lack of evidence, and when evidence
is available, it may be difficult to interpret and to apply in a
specific clinical setting. Furthermore, recommendations
based on evidence are not always balanced and, therefore,
it seems appropriate to propose recommendations after an
expert group has reviewed the evidence and examined it in
the context of the disease and of all forms of interventions.2
Clinicians sometimes feel that evidence-based medicine
tends to devaluate the value of individual clinical expertize
and that the focus is shifted away from the care of individual
patients towards the care of populations.2 According to the
definition of Sackett,25 however, evidence-based medicine
should not cancel the value of individual clinical expertize
but should be regarded as ‘‘the conscientious, explicit and
judicious use of current best evidence in making decisions
about the care of the individual patient. It means integrat-ing individual clinical expertize with the best available
external clinical evidence from systematic research.’’The expert panel at the basis of guideline
development (Table 3)
To allow the successful development of a guideline, a group
of people, each exerting a specific role in the guideline
generation process, is required. This guideline panel consists
of a team leader, who co-ordinates the group process and
the group task, and several group members providing
specialist resource, technical and administrative support.
As many clinical conditions, including allergy and AR, are
preferentially managed in a multidisciplinary setting, it is
also recommended that the expert panel have a multi-
disciplinary composition. Furthermore, different back-
grounds of the panel members may lead to a better
balancing of individual biases.
The group members function as experts in their field and
contribute to the generation of the guideline recommenda-
tions by sharing their experience with clinical practicalities
and their knowledge on the available evidence. According to
Shekelle, the panel should consist of at least 6, but no more
than 12–15 members, as too few members limits adequate
discussion and too many members hampers effective
functioning of the group.17 Following these recommenda-
tions, the expert panel at the basis of the International
Consensus Statement of Rhinitis3 and the ARIA guidelines7
are too large, consisting of 18 and 37 members, respectively,
whereas the EAACI guidelines group,4 ideally, was composed
of 11 experts. Nevertheless, the recommendations on the
number of panel members can be debated. Probably, large
groups can also function adequately if the tasks are shared
by subgroups, reporting the larger group at the end.
In a systematic review of 91 studies, Grimshaw and
Russell26 concluded that guidelines have the greatest chance
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clinicians for whom they are intended. The representation
of the end-users in the guideline development group is
indeed of great value for the identification of the specific
needs of the end-users and for the adaptation of data from
research into useful and user-friendly recommendations for
the practitioner. Guidelines for the management of AR are
not only aimed for specialists, but are intended to assist GPs
in particular. The important end-user group of GPs however,
was not represented in the expert panel from the Interna-
tional Consensus Report3 and the EAACI guidelines.4 The
ARIA panel7 on the other hand, consisted of both specialists
(Otorhinolaryngologists, Allergologists, Pulmonologists, Pae-
diatricians) and GPs.
Although often neglected, not only GPs and specialists,
but also pharmacists can play a key role in the prevention,
recognition and treatment of AR. The involvement of
pharmacists in the collaborative management of AR is also
recognized by ARIA, and is sustained by the recent
publication of the ‘ARIA in the Pharmacy’ guidelines. This
document is aimed as a practical stepwise guide for
pharmacists and their staff in the recognition and manage-
ment of patients suffering from AR.27 The working group at
the basis of the Pharmacy guidelines consists of 22 members,
18 males and 4 women, of whom 6 have a degree in
Pharmacy.
If guidelines are intended for international use, it is
necessary that experts from the different countries and
continents are involved in their generation and formulation
and in adapting them to meet local needs and local socio-
economic and health care standards and resources. The ARIA
guidelines were developed for the whole world and their
global character is also reflected in the international and
intercontinental composition of the ARIA panel.
In all rhinitis guideline groups, women and experts
affiliated to non-university institutions are clearly under-
represented and the selection of a more balanced composi-
tion of the panel for gender and professional background
and affiliation should be considered in the future.
Another consideration is that independence of pharma-
ceutical industry is strictly necessary if guidelines are
intended to be used as a basis for physicians and health
care organizations, and any conflict of interest of the
authors must be reported. In the European guidelines,3,4
conflict of interest among the members of the expert panel
was not disclosed. For the ARIA group, conflict of interest
was reported to the WHO for all except one member, but
this was not published in the ARIA report (Table 3).Efficacy and validity of guidelines
The central role of guidelines is to assist health care
providers in the management of their patients and to
improve the patient care, compliance and satisfaction.
Despite the vast number of guidelines and the increasing
attention paid to the methodology of guideline develop-
ment, there is limited evidence of the efficacy of guidelines
to change physician’s and patient’s behaviour and their
impact on practice patterns, health outcomes and health-
care costs.28The International Consensus on Rhinitis3 is the only
guideline for AR that has been assessed for its effects on
health outcomes. A multicentre, randomized, parallel group
study compared treatment according to the Rhinitis Con-
sensus with free choice treatment in patients with seasonal
AR6 and demonstrated that implementation of the guide-
lines was significantly better than treatment according to
the GPs’ free choice, as reflected by reduced symptom
scores and increased quality of life, patient compliance and
satisfaction. Costs were not evaluated.29
In this trial GP’s in the guideline group were explicitly
asked to follow the guideline recommendations, whereas, in
real life, availability of guidelines does not ensure the use of
guidelines. Physician’s attitude towards and adherence to
clinical guidelines should therefore be evaluated as an
intermediate step to measuring effectiveness of clinical
practice guidelines based on patient outcomes.
There is a strong need for valid instrument to measure
practitioner’s attitudes towards guidelines. Some scales
have been proposed, but often they do not have satisfactory
psychometric properties and lack of reliability and valid-
ity.30 Discrepancies between what doctors state they do or
think about guidelines and what they actually do have been
noted.31 Furthermore, a clinician’s attitude towards a
guideline can change over time as a result, for instance,
of recent positive or negative experiences with the use of a
particular guideline.
Overall, measurement of practice patterns and guideline
adherence has relied on health care claims and medical
records data.32,33 However, validly measuring physician
adherence requires assessment of patient/physician com-
munication, collaborative decision-making, patient prefer-
ence for quality of life and treatment goals, and elicitation
of patient adherence to physician recommendations. Nu-
merous and varied biases including patient, physician and
organizational biases affect the generalizability or applic-
ability of guideline recommendations to clinical practice.
Additionally, these factors undermine measurement and
evaluation of practice patterns and physician’s adherence to
guidelines.34
According to our knowledge, no study assessing the
efficacy of AR guidelines to change physician and patients
behaviour has been published. Further efforts are required
to develop valid and reliable instrument to assess physician’s
attitude towards guidelines, and to evaluate physician’s and
patient’s compliance with guideline recommendations. In
addition, factors influencing adherence to guidelines need
to be further identified.Worldwide applicability of AR guidelines
The EAACI guidelines4 assume that the recommended
treatments are available and financially affordable to the
patient, and do not consider these situations where the
suggested first-choice treatment is not an option. The 1994
International Consensus Report3 does mention that all
recommendations of treatment strategies depend upon
local availability of the therapeutic interventions, but does
not formulate any concrete suggestions or recommenda-
tions.
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Table 4 Situations that require a guideline to be
updated, adapted from Shekelle et al.36
1. Changes in the available interventions
2. Changes in the evidence on the benefits and harms of
existing interventions
3. Changes in the outcomes that are considered
important
4. Changes in the values placed on outcomes
5. Changes in evidence that current practice is optimal
6. Changes in resources available for health care
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management of AR worldwide and consider the costs and
supply problems of pharmacological therapies and the
limited health care facilities in low-income countries. Some
recommendations are made for a standardized management
of AR in developing countries: first-line treatment with oral
first generation antihistamine chlorpheniramine on demand
is suggested for mild intermittent rhinitis; high doses
intranasal beclomethasone with step-up and step-down
options for moderate/severe intermittent rhinitis; chlor-
pheniramine or low doses intranasal beclomethasone for
mild persistent rhinitis and high dose intranasal beclo-
methasone is the first-choice therapy in case of moderate/
severe persistent rhinitis.7 This of course raises the question
whether it is ethically correct to recommend a first
generation antihistamine, with its well-known side-effects,
sedation in particular, when second generation antihista-
mines are too expensive or unavailable.
Furthermore, to guarantee the global applicability of
guidelines, not only differing health care resources and
facilities, but also many other issues need to be considered.
Most of the studies at the basis of guideline recommenda-
tions and validations have been carried out in developed,
westernized countries. Different races, however, may
metabolize drugs differently, cultural and behavioural issues
may play a role in differing populations, and risk versus
benefit arguments regarding therapeutic decisions may also
vary between populations. The risks associated with steroid
therapy for instance, may possibly be greater when the
patient is malnourished or paradoxically less when life
expectancy is anyway low.35Up to date information and revision
To be valuable and useful in clinical practice, it is
particularly important that guidelines are based on current
scientific knowledge and that they are regularly revised and
updated. Systematic evaluation of the validity of guidelines
involves the identification of new information and assess-
ment whether these new insights warrant guideline updat-
ing. There is, however, no consensus on the time interval
and the methodology to perform a guideline update.
Defining an arbitrary prescheduled date for reviewing and
updating clinical practice guidelines is not practical. Under-
taking a full update prematurely is a waste of resources,
while guidelines on topics in full and rapid expansion on the
other hand, may become outdated long before the
scheduled review date.
Conducting a new, complete systematic review, starting
from the end date of the original guideline search, is
definitely the most thorough way to identify significant new
evidence, but is very effort-, time- and money-consuming. A
more feasible method, is to first assess whether guideline
updating is required through an efficient screening process.
Table 4 describes six situations that require a guideline or
guideline recommendation to be updated (or even with-
drawn). Shekelle et al.36 proposed a pragmatic model to
identify potentially significant new evidence, consisting of a
limited but focused literature search under the multi-
disciplinary guidance and critical appraisal of experts.
Recently, this model was compared with a traditionalsystematic review method and it was validated as an
efficient and acceptable method.37 To get an idea
about the rate at which guidelines become outdated,
Shekelle et al. also used their conceptual strategy to
assess the validity of 17 clinical practice guidelines,
published by the Agency for Health care Research and
Quality (AHRQ). Survival analysis indicated that about half
of the guidelines became outdated in 5.8 years and that no
more than 90% of the guidelines were still valid 3.6 years
after delivery of the guideline to the AHRQ. Based on these
findings, the authors suggest that the best interval to assess
whether guidelines are still up-to-date should be conserva-
tively after a 3 years time period, when 90% of the
guidelines are estimated to be still valid. For topics that
are characterized by rapid scientific advances, a shorter
interval may be indicated, for topics that are more stable a
longer interval.38
It is important to remark that often, there is a large time
lag between the end date of literature search and the
publication date of a guideline in a paper journal. For the
ARIA guidelines the literature search ended on December
31st 1999, whereas the guidelines were only published 2
years later (November 2001). The EAACI guidelines on the
other hand, were based on the literature data available by
May 1999 and the document was already published in
February 2000. The International Consensus on Rhinitis, was
published in 1994, but does not specify the end date of the
literature search. According to the reference list, however,
it must have been somewhere end 1993. This implies that it
took 5–6 years before the European guidelines on rhinitis
were updated, which is too long for a rapidly evolving topic,
such as AR. Between the end dates of the literature search
at the basis of the EAACI and the ARIA guidelines, on the
other hand, there’s only an interval of 7 months. This is of
course reflected by the significant overlap between these
two guidelines. Nevertheless, the ARIA report contains much
more extensive and detailed information on the epidemiol-
ogy, pathophysiology, diagnostic and therapeutic options for
AR. And, more importantly, the ARIA recommendations are
based on evidence, whereas the recommendations of the
EAACI guidelines were still based on expert opinion and
consensus.
At present, our most recent international and evidence-
based guidelines for AR, the ARIA guidelines, are based on
data that were already available 6 years ago. Since then,
insights in the mechanisms at the basis of AR development
and symptom manifestation have further expanded, the
nomenclature for allergic disorders has been reviewed,39 an
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lished, new treatments have extensively been investigated
and some are ready to take a place in the therapeutic
algorithms for AR. Furthermore, since the publication of the
ARIA guidelines, there have been more than 4 years to
identify the strong and weak points of these guidelines, to
test the validity, usefulness and userfriendliness of the
recommendations in clinical practice and to collect feed-
back from the guideline-users.
Guideline development and updating should, in fact, be
considered as a continuous process, rather than as a discrete
event. This ongoing process could consist of regular
automated literature searches and revision of relevant
citations by members or subgroups of the guideline panel,
followed by evaluation of the impact of new evidence on the
validity of an existing guideline. Furthermore, if guidelines
are available in an electronic form on the Web, recommen-
dations that are considered as outdated or invalid could
easily and systematically be deleted or changed by updating
the underlying inputs. In addition, a mechanism could be
added to electronically alert interested parties that changes
have been made to the guideline.38Translating research into practice, dissemination
and implementation of guidelines
There remains a large gap between clinical research and
clinical practice and the development of clinical practice
guidelines does not ensure their use in medical practice.
Translating scientific knowledge into practical medicine is
not straightforward and may be hampered by diverse
structural, cultural, economic or behavioural barriers.
Budgetary limitations, competing demands and restricted
health care facilities in low-income countries have already
been addressed. However, also in developed countries,
allergy (and AR) has only recently gained a place on the
agenda of Governments and Health Departments. In the
individual patient care setting, physicians’ adherence to
guidelines may be restricted by lack of awareness, lack of
familiarity, lack of self-efficacy, lack of outcome expectancy
and by inertia of previous practice. Lack of time, lack of
reimbursement for following guidelines or limited staff have
also been put forward as barriers. Furthermore, physicians
may experience difficulties in reconciling patient prefer-
ences with guideline recommendations, and sometimes
guidelines themselves may be confusing or unclear.35,40
Finally, barriers may also rise at the level of the patient, in
terms of compliance with the recommended therapeutic
strategies.
To address the gap between research and practice,
clinical guidelines should be simple, transparent, informa-
tive and adapted to the clinical setting, the cultural and
socio-economical context. The main goal of guidelines is to
assist physicians and to improve patient care. This implies
that they should be developed and considered as a support
for practitioners with space for flexibility, rather than as a
set of constrained rules.2
There is no single effective way to introduce and ensure
the use guidelines into practice, but a carefully developed
and multifaceted dissemination and implementation pro-gram should form an integrated part of the stepwise and
continual process of guideline production.
Dissemination usually starts with the publication of the
full version guideline report in a professional journal. For
practitioners—GPs in particular—taking care of patients
with multiple diseases, however, it is impossible to read
through these often very voluminous documents. The GINA
Workshop Report for asthma for example is 176 pages long41
and the ARIA Workshop Report is 187 pages long.7 More
useful and userfriendly is the distribution of guideline
summaries or pocket guides, which have been developed
for both the GINA and the ARIA guidelines. They provide key
messages and structured decisional algorithms, whereas the
full guideline reports may be consulted for additional
background information.
Over the last years the World Wide Web has gained
interest as an alternate medium for guideline developers to
disseminate guidelines. Web-based guidelines can incorpo-
rate a greater complexity than that afforded by paper-based
format while maintaining a consistent structure and
orientation for the user. The level of detail displayed can
be varied and easy linking to supporting material is
possible.42 Web-based guidelines allow distance-learning
and are more easily distributed, modified and updated.
Furthermore, there is a growing interest in Web-based
models to create global guidelines based on decision models
that can be disseminated over the web. Local guideline
users could then alter the input underlying the decision
model and tailor the guidelines to a particular patient
population.43 At present, however, research into Web-based
guidelines is still in the early stages. The strengths and
weaknesses of Web-based guidelines need to be further
elucidated and the exact role of Web-based guidelines as a
primary or secondary modality added to the traditional
paper-based guidelines needs to be defined.
Furthermore, relatively passive methods of publication in
professional journals or mailing to targeted health care
professionals alone, are unlikely have an impact on
professional acting.44,45 The dissemination and implementa-
tion process should be arranged to take the intervention
closer to the doctor/patient setting. In a systematic review
of 91 studies, Grimshaw and Russell26 concluded that
guidelines have the greatest chance of changing clinical
behaviour when they are disseminated via specific educa-
tional interventions, followed by continuing medical educa-
tion, and implemented via patient-specific reminders during
the consultation. A Cochrane Review analysed the effects of
continuing education sessions and concluded that interac-
tive workshops can result in moderately large changes in
professional practice, whereas didactic sessions alone are
unlikely to change professional practice.46 Other profes-
sional interventions that may lead to further reinforcement
of guideline messages are reminders, audit and feedback.35
As for Web-based guidelines, Web-based learning in general
possibly has a valuable educational contribution, but its full
potential needs to be unlocked and its exact role needs to
be established, Of course quality control of the dissemi-
nated information must be warranted and the principles of
effective learning must be integrated.
At present, there is insufficient evidence to allow an
estimation of the efficiency and cost-effectiveness of the
diverse professional dissemination and implementation
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this area is required to develop and validate a coherent
framework that may sustain the process of introducing and
establishing guidelines into clinical practice and may
consequently result in significant improvements in educa-
tional outcomes and healthcare practices.47
Organizational interventions (e.g. expanded role of the
pharmacist), financial interventions (e.g. professional in-
centives) and regulatory interventions (e.g. giving GPs
access to specific diagnostic tests) have also been suggested
to facilitate or stimulate the use of guidelines in clinical
practice.39 However, caution should be paid to the implica-
tion of legal authorities or national health organizations in
the process of guideline development, dissemination and
implementation. Leaning on guidelines to guide or support
governmental and health care policy decisions might
generate discussions on the type of guidelines that should
be used (e.g. national versus international). In addition, it is
associated with a potential risk of basing such important
decisions on outdated guidelines, and of course it may imply
a restriction of medical freedom.
The final and most important step of putting guidelines
into practice occurs at the level of the patient. Even if
guidelines ensured the best clinical practice in the world, if
patient’s behaviour and knowledge is inappropriate, the
outcomes may not change much. Patients should be
considered as effective partners in health care. Educating
the patient regarding the nature and management of their
disease, teaching them how to verify received information,
how to present symptoms and clinical history and how to
assess outcomes can maximize compliance, increase satis-
faction and optimize health outcomes. Furthermore,
patient’s feedback may act as a stimulus to health
professional change.
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